Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on August 18, 2017, the compensation committee of the Company's board of directors granted nine new employees options to purchase an aggregate of 56,725 shares of the Company's common stock and 22,364 restricted stock units. Each stock option has an exercise price per share equal to $18.22, which was the closing trading price on the date of the grant. The stock options and restricted stock units were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's board of directors in December 2014 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. The Company’s second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Investor Contact: Matthew Duffy 212.915.0685 [email protected] Media Contact: David Arrington Vice President, Investor Relations and Corporate Communications 650.440.5856 [email protected]
